Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

Now Viewing

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Sequencing Strategies and Resistance Management

Key Themes:

• Impact of adjuvant alectinib use (ALINA) on sequencing strategies
• Selection of post-frontline therapies after ALK inhibitor progression
• Role of resistance mutations in therapy selection
• Emerging data on NVL-655 (from ESMO 2024)

Notable Insights:

• Dr Dietrich explored how adjuvant ALK inhibitor exposure might influence frontline metastatic therapy selection

Dr Lovly discussed strategies for selecting therapies after progression, including considerations of resistance mutations and data on NVL-655